What is the appropriate intravenous amoxicillin‑clavulanate (Augmentin) dosing for pediatric patients based on weight, age, and renal function?

Intravenous Amoxicillin-Clavulanate Dosing for Pediatric Patients

For pediatric patients of all ages requiring intravenous amoxicillin-clavulanate, administer 30 mg/kg of the amoxicillin component every 8 hours (three times daily). 1

Standard IV Dosing Algorithm

Weight-Based Calculation

• Calculate the dose as 30 mg/kg of the amoxicillin component administered every 8 hours (three times daily) via intravenous infusion 1
• Infuse each dose over 30 minutes to optimize pharmacokinetics and minimize infusion-related adverse effects 2
• The maximum single dose should not exceed 2 g per administration, regardless of weight 1

Practical Dosing Examples by Weight

• 10 kg child: 300 mg IV every 8 hours
• 20 kg child: 600 mg IV every 8 hours
• 30 kg child: 900 mg IV every 8 hours
• ≥40 kg child: Use adult dosing regimens 3

Critical Dosing Adjustments

Severe Infections & Augmented Clearance

• In critically ill children after cardiac surgery or those with augmented renal clearance, increase dosing frequency to every 6 hours (four times daily) to maintain adequate drug exposure 2
• Children not receiving vasopressors demonstrate remarkably high clearance and may require every 4-hour dosing to achieve 50% time above MIC for resistant organisms 2
• Patients on vasopressor support have approximately 1/3 reduction in clearance, making standard 6-hourly dosing adequate 2

Renal Insufficiency

• For children with established renal insufficiency, prolong the dosing interval according to creatinine clearance to avoid drug accumulation 1
• Both amoxicillin and clavulanic acid are renally eliminated, requiring significant dose reduction in altered renal function 1

Age-Specific Considerations

Infants ≥3 Months

• The standard 30 mg/kg every 8 hours regimen is appropriate for infants ≥3 months of age 1
• Safety and efficacy data are robust for children ≥3 months but remain limited for younger infants 1

Infants <3 Months

• For infants younger than 3 months with suspected serious bacterial infection, intravenous ampicillin + gentamicin or cefotaxime are preferred over amoxicillin-clavulanate 1
• If IV amoxicillin-clavulanate is deemed absolutely necessary in a 1-2 month old infant, obtain specialist consultation before prescribing 1

Pharmacokinetic Evidence

Drug Exposure & Half-Life

• A single IV dose of 25 mg/kg amoxicillin + 5 mg/kg clavulanate achieves mean plasma concentrations of 89.4 mcg/mL amoxicillin and 19.5 mcg/mL clavulanate at 5 minutes post-infusion 4
• Terminal plasma half-lives are 1.2 hours for amoxicillin and 0.8 hours for clavulanate in pediatric patients 4
• These pharmacokinetic parameters support every 6-hour dosing (25 mg/kg amoxicillin + 5 mg/kg clavulanate) as a reasonable starting regimen for noninvasive childhood diseases 4

PK/PD Target Attainment

• The pharmacodynamic target for amoxicillin is 40-50% time above MIC 2, 5
• For bacterial MICs of 8 mg/L, only 65% of hospitalized patients achieve 40%T>MIC with standard dosing 5
• Increasing to 6 times daily dosing improves target attainment to 95% for severe infections 5

Common Clinical Pitfalls

Underdosing in Critically Ill Patients

• Augmented renal clearance in postoperative cardiac surgery patients leads to subtherapeutic concentrations with standard 8-hourly dosing 2
• Failure to increase dosing frequency in critically ill children without vasopressor support results in clinical failure 2

Inappropriate Use in Neonates

• Pharmacokinetic studies demonstrate reliable metabolism and clearance of clavulanate only after the neonatal period (≥3 months), supporting the age cutoff 1
• Routine use in infants <3 months is not recommended due to limited safety data 1

Inadequate Infusion Time

• Rapid IV push administration should be avoided; infuse over 30 minutes to optimize drug exposure and tolerability 2

Transition to Oral Therapy

Switching Criteria

• Switch from IV to oral amoxicillin-clavulanate as soon as clinically appropriate when the patient can tolerate oral intake and shows clinical improvement 6
• Oral high-dose regimen is 90 mg/kg/day of amoxicillin component with 6.4 mg/kg/day clavulanate, divided into 2 doses 1

Expected Clinical Response

• Clinical improvement (reduced fever, better respiratory status) should be evident within 48-72 hours of initiating appropriate IV therapy 1, 3
• If no improvement or worsening occurs after 48-72 hours, reassess the diagnosis and consider atypical pathogens or complications 1, 3

Microbiological Coverage

• IV amoxicillin-clavulanate provides coverage against β-lactamase-producing Haemophilus influenzae, Staphylococcus aureus (MSSA), Streptococcus species, Neisseria species, and Moraxella catarrhalis 4
• The addition of clavulanate is essential for clinical success against β-lactamase producers, with eradication rates approaching 100% when the combination is used 3